Valeant Pharmaceuticals International

Ardea Biosciences, Inc

Other

Abbvie Inc.

Huanming Chen

Jean-Michel Andre Vernier

Jim Zhen Wu

Jianlan Song

Zhi Hong

Robert C Tam

Martha Alicia De La Rosa

Andreas Maderna

Stanley Lang

Dinesh Barawkar

Varaprasad Chamakura

Ian Wayne Cheney

Gary Lee Larson

Thomas Dale Penning

Anil Vasudevan

Marina Pliushchev

Yan Rong Shen

Bo Liang

Hassan El Abdellaoui

Zhenguang Zou

Shaohui Wang

Anneke K Raney

Cuihua Liu

Fengchun Wu

Hassan Abdellaoui

Jenny Song

Compounds of formula (I) or pharmaceutical acceptable salts are provided, wherein X&#x2dc;X, R&#x2dc;R, A, B, Z and n are defined in the description. And compositions containing said compounds, and the uses for inhibitors of kinases such as ALK, and the uses for treating cancer thereof are provided. 

Bicyclic carboxamide inhibitors of kinases

This invention provides a compound of formula A The compound provided herein can affect the opening of, or otherwise modulate, voltage-gated potassium channels. The compound provided herein is useful for the treatment and prevention of diseases and disorders which are affected by activation or modulation of potassium ion channels. One such condition is seizure disorders.

N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators

This invention provides compounds of formula A and formula B which are modulators of potassium ion channels and are useful for the treatment of seizure disorders.

N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators

The present invention relates to benzyloxyanilide derivatives having the following structural formula: The compounds of the present invention are useful for the treatment and prevention of diseases and disorders which are affected by activation or modulation of potassium ion channels. One such condition is seizure disorders.

Benzyloxy anilide derivatives useful as potassium channel modulators

This invention provides compounds of formula I where Aris a 5- to 10-member mono- or bicyclic aromatic group, optionally substituted; where the &#x2014;NRRgroup is situated ortho to the NHC(&#x2550;X) group; n=1 or 2; X=O or S; Y is O or S; and q=1 or 0. The invention also provides pharmaceutical compositions comprising compounds of formula I and/or salts, esters, and prodrugs thereof. These compounds modulate the activation and inactivation of potassium channels. The compounds are useful for the treatment and prevention of diseases and disorders&#x2014;such as seizure disorders&#x2014;which are affected by modulation of potassium ion channels.

[object Object]

This invention provides a compound of formula IA where X&#x2550;O or S; Y is O or S; q=1 or 0; and other substituents are defined herein. Such compounds can affect the opening of, or otherwise modulate, voltage-gated potassium channels. They are potentially useful for the treatment and prevention of diseases and disorders which are affected by activation or modulation of potassium ion channels. One such condition is seizure disorders.

Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators

This invention provides compounds of formula I where the dashed line represents an optional double bond;where Ris phenyl, naphthyl, pyridyl, pyrimidyl, pyrrolyl, imidazolyl, pyrazyl, furyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl, optionally substituted, and other substituents are defined herein. Such compounds are potassium channel modulators.

Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators

This invention provides compounds of Formula I which are inhibitors of Chk2 and are useful as a radiation protection agents in anticancer radiotherapy. A method of modulating Chk2 in vitro includes treating a substrate with Chk2 in the presence of compounds of formula I. A method of making a compound of formula I includes: a) forming a biaryl amine having an amino (NH) group; b) converting the amino group to an isothiocyanate group; c) adding a cyanoacetamide to the isothiocyanate group to form a thioamide adduct; d) cyclizing the thioamide adduct to form an isothiazole having a cyano group; and e) adding an amine to the cyano group to form a carboxamidine group.

3-hydroxyisothiazole-4-carboxamidine derivatives as CHK2 inhibitors

This invention is directed to compounds of formula I, where G is &#x2014;O&#x2014;, &#x2014;S&#x2014;, &#x2014;C(g)(g)-, or &#x2014;NH&#x2014;, and n=1, 2, or 3. Such compounds modulate potassium channels. The compounds are useful for the treatment and prevention of diseases and disorders which are affected by modulation of potassium ion channels. One such condition is seizure disorders.

1,4 diamino bicyclic retigabine analogues as potassium channel modulators

This invention provides compounds of formula I  These compounds modulate the activation and inactivation of potassium channels. The compounds are useful for the treatment and prevention of diseases and disorders&#x2014;such as seizure disorders&#x2014;which are affected by modulation of potassium ion channels.

The invention concerns compounds which inhibit MEK and which have activity as anti-neoplastic agents. These compounds include N-substituted-3-hydroxy-5-arylamino-isothiazole-4-carboxamidines. Also included are the tautomeric isothiazol-3(2H)-ones.

Phenylamino isothiazole carboxamidines as MEK inhibitors

This application relates to novel fused tricyclic thienopyridines of Formulas I and II, which useful for treating Hepatitis B infection and other diseases. This application also relates to pharmaceutical compositions comprising thienopyridines and to the use of such compositions to treat Hepatitis B and other diseases.

Growing community of inventors

Irvine, CA, United States of America

Huanming Chen